SOOLANTRA

Peak

ivermectin

Galderma
NDATOPICALCREAM
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6

Mechanism of Action

Pharmacologic Class:

Antiparasitic

Clinical Trials (5)

NCT03301649Phase 3Completed

Clinical Endpoint Study of Ivermectin 0.5% Lotion

Started Oct 2017
905 enrolled
Head Lice
NCT03286101Phase 2Completed

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

Started Sep 2017
120 enrolled
Pediculosis Capitis
NCT00921219Phase 1Completed

Ivermectin Solution Bioequivalence Study - With Food (Repeat)

Started Sep 2005
34 enrolled
Healthy
NCT00921154Phase 1Completed

Ivermectin Solution Bioequivalence Study - Fasted

Started Mar 2005
24 enrolled
Healthy
NCT00921674Phase 1Completed

Ivermectin Solution Bioequivalence Study - With Food

Started Feb 2005
24 enrolled
Healthy

Loss of Exclusivity

LOE Date
Mar 13, 2034
97 months away
Patent Expiry
Mar 13, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
10206939
Mar 13, 2034
U-1631
9089587
Mar 13, 2034
U-1631
9233117
Mar 13, 2034
U-1631
9233118
Mar 13, 2034
U-1631
9782425
Mar 13, 2034
U-1631
Company
Galderma
Galderma
TX - Dallas
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers